Active versus sham DLPFC-NAc rTMS for depressed adolescents with anhedonia using resting-state functional magnetic resonance imaging (fMRI): a study protocol for a randomized placebo-controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2024-01, Vol.25 (1), p.44-44, Article 44
• Main Authors: Lv, Runxin, Cai, Min, Tang, Nailong, Shi, Yifan, Zhang, Yuyu, Liu, Nian, Han, Tianle, Zhang, Yaochi, Wang, Huaning
• Format: Article
• Language: English
• Subjects: Adolescent; Anhedonia; Anxiety disorders; Care and treatment; Cognitive behavioral therapy; Consent; Depressive disorder; Depressive Disorder, Major - diagnostic imaging; Depressive Disorder, Major - therapy; Diagnosis; Dorsolateral Prefrontal Cortex; Evaluation; FDA approval; Health aspects; Humans; Hypotheses; Intervention; Magnetic Resonance Imaging; Major; Major depressive disorder; Mental depression; Mental disorders; Neuromodulation; Nucleus accumbens; Participation; Prefrontal Cortex - diagnostic imaging; Psychological aspects; Randomized Controlled Trials as Topic; Substance abuse treatment; Teenagers; Transcranial magnetic stimulation; Transcranial Magnetic Stimulation - adverse effects; Transcranial Magnetic Stimulation - methods; Treatment Outcome; Youth
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-023-07814-y

Anhedonia, which is defined as the inability to feel pleasure, is considered a core symptom of major depressive disorder (MDD). It can lead to several adverse outcomes in adolescents, including heightened disease severity, resistance to antidepressants, recurrence of MDD, and even suicide. Specifically, patients who suffer from anhedonia may exhibit a limited response to selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT). Previous researches have revealed a link between anhedonia and abnormalities within the reward circuitry, making the nucleus accumbens (NAc) a potential target for treatment. However, since the NAc is deep within the brain, repetitive transcranial magnetic stimulation (rTMS) has the potential to modulate this specific region. Recent advances have enabled treatment technology to precisely target the left dorsolateral prefrontal cortex (DLPFC) and modify the functional connectivity (FC) between DLPFC and NAc in adolescent patients with anhedonia. Therefore, we plan to conduct a study to explore the safety and effectiveness of using resting-state functional connectivity magnetic resonance imaging (fcMRI)-guided rTMS to alleviate anhedonia in adolescents diagnosed with MDD. The aim of this article is to provide a study protocol for a parallel-group randomized, double-blind, placebo-controlled experiment. The study will involve 88 participants who will be randomly assigned to receive either active rTMS or sham rTMS. The primary object is to measure the percentage change in the severity of anhedonia, using the Snaith-Hamilton Pleasure Scale (SHAPS). The assessment will be conducted from the baseline to 8-week post-treatment period. The secondary outcome includes encompassing fMRI measurements, scores on the 17-item Hamilton Rating Scale for Depression (HAMD-17), the Montgomery Asberg Depression Rating Scale (MADRS), the Chinese Version of Temporal Experience of Pleasure Scale (CV-TEPS), and the Chinese Version of Beck Scale for Suicide Ideation (BSI-CV). The Clinical Global Impression (CGI) scores will also be taken into account, and adverse events will be monitored. These evaluations will be conducted at baseline, as well as at 1, 2, 4, and 8 weeks. If the hypothesis of the current study is confirmed, (fcMRI)-guided rTMS could be a powerful tool to alleviate the core symptoms of MDD and provide essential data to explore the mechanism of anhedonia. ClinicalTrials.gov NCT05544071. Registered on 16 September 20